INTERVENTION THERAPIES FOR INSULIN-DEPENDENT DIABETES

被引：7

作者：

MUIR, A

SCHATZ, DA

POZZILLI, P

MACLAREN, NK

机构：

[1] Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL

[2] Department of Pathology and Laboratory Medicine, International Diaetes Intervention Group (IDIG)

[3] Department of Pathology and Laboratory Medicine, International Diaetes Intervention Group (IDIG)

[4] Department of Pediatrics, International Diaetes Intervention Group (IDIG)

来源：

AUTOIMMUNITY | 1993年 / 16卷 / 04期

关键词：

IMMUNOSUPPRESSION; NICOTINAMIDE; PREVENTION; PATHOGENESIS; MULTICENTER;

D O I：

10.3109/08916939309014650

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Treatment of insulin-dependent diabetes remains problematic since there continues to be high rates of morbidity and mortality among affected patients. Good outcomes are most likely to be more common among patients who maintain endogenous insulin reserves for the longest time following diagnosis. The disease process can now be identified in its early, pre-symptomatic stages and thus, the time has come for the investigation of preventive therapies through multicenter clinical trials. A wide variety of strategies are available and their choice should be dependent on the pathogenic stage of disease at which treatment is initiated. This stage-specific approach to prevention is discussed with a particular focus on those therapies that will soon be tested in clinical trials.

引用

页码：301 / 310

页数：10

共 80 条

[1]

Ford E.S., Destefano F., Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I epidemiologic follow-up study, Am J Epidemiol, 133, pp. 1220-1230, (1991)

[2]

Major cross-country differences in risk of dying for people with IDDM, Diabetes Care, 14, pp. 49-54, (1991)

[3]

Viberti G., Etiology and prognostic significance of albuminuria in diabetes, Diabetes Care, 11, pp. 840-845, (1988)

[4]

Brownlee M., Vlassara H., Cerami A., Nonenzymatic glycosylation and the pathogenesis of diabetic complications, Arm Intern Med, 101, pp. 527-537, (1984)

[5]

Muir A., Schatz D.A., Maclaren N.K., The pathogenesis, prediction, and prevention of insulin-dependent diabetes mellitus, Endocrinology and Metabolism Clinics of North America, pp. 199-219, (1992)

[6]

Cyclosporin-induced remission of IDDM after early intervention: Association of 1 yr of cyclosporin treatment with enhanced insulin secretion, Group Canadian-European Randomized Control Trial, 37, pp. 1574-1582, (1988)

[7]

Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., Factors associated with early remission of type 1 diabetes in children treated with cyclosporine, N Engl J Med, 318, pp. 663-670, (1988)

[8]

Silverstein J., Maclaren N., Riley W., Spillar R., Radjenovic D., Johnson S., Immunosuppression with Azathioprine and Prednisone in recent-onset insulin-dependent diabetes mellitus, N Engl J Med, 319, 10, pp. 599-604, (1988)

[9]

Martin S., Schernthaner G., Nerup J., Gries F.A., Koivisto V.A., Dupre J., Follow-up of Cyclosporin A Treatment in Type 1 Insulin Dependent Diabetes Mellitus: Lack of Long-Term Effects, Diabetologia, 34, pp. 429-434, (1991)

[10]

Maclaren N.K., Perspectives in diabetes:How, when, and why to predict IDDM, Diabetes, 37, 12, pp. 1591-1994, (1988)

← 1 2 3 4 5 6 7 8 →